Loading...
XKRX
199800
Market cap428mUSD
Aug 16, Last price  
75,300.00KRW
Name

ToolGen Inc

Chart & Performance

D1W1MN
P/E
95.66
P/S
669.09
EPS
787.17
Div Yield, %
—
Shrs. gr., 5y
4.12%
Rev. gr., 5y
-4.56%
Revenues
891m
-19.25%
1,501,978,8202,116,891,1401,540,265,3803,338,322,4501,156,831,6301,125,062,520713,092,8801,597,275,450743,463,6101,103,409,420890,961,030
Net income
6.23b
P
147,611,300-5,147,179,190-3,016,631,450-4,342,908,080-8,056,827,180-16,277,597,380-14,733,351,780-20,730,863,000-18,177,221,000-42,340,173,0006,231,842,130
CFO
-16.46b
L+10.39%
324,280,670-292,680,200-3,356,198,850-1,785,240,650-6,290,853,680-9,974,249,260-10,070,210,380-14,827,687,150-14,986,540,420-14,907,423,230-16,456,995,760

Profile

ToolGen Inc is a biotechnology company, which focuses on the development of genome editing technology. Its products include gRNA/Cas9 purified, gRNA/Cas9, and recombinant Cas9 protein, which offers ready-to-use reagents for genome engineering experiments. The company also offers genome-edited cell line; genome-edited mouse/rat; and genome-edited plant services, as well as surrogate reporter synthesis and in-del analysis services.
URL
http://www.toolgen.com/
IPO date
Jun 25, 2014
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
890,961
-19.25%
1,103,409
48.41%
743,464
-53.45%
Cost of revenue
16,334,783
11,977,208
12,717,657
Unusual Expense (Income)
NOPBT
(15,443,822)
(10,873,799)
(11,974,193)
NOPBT Margin
Operating Taxes
67
Tax Rate
NOPAT
(15,443,822)
(10,873,799)
(11,974,260)
Net income
6,231,842
-114.72%
(42,340,173)
132.93%
(18,177,221)
-12.32%
Dividends
Dividend yield
Proceeds from repurchase of equity
21,795,849
1,006,601
962,043
BB yield
-0.22%
Debt
Debt current
13,897,097
21,752
19,095
Long-term debt
273,131
60,514,899
20,866
Deferred revenue
Other long-term liabilities
1,285,709
1,175,683
1,102,050
Net debt
(3,536,044)
24,578,991
(17,324,649)
Cash flow
Cash from operating activities
(16,456,996)
(14,907,423)
(14,986,540)
CAPEX
(458,843)
(6,684,456)
(5,380,948)
Cash from investing activities
(2,593,190)
(716,215)
17,609,013
Cash from financing activities
810,893
33,964,301
887,512
FCF
(14,539,825)
(13,896,140)
(17,195,906)
Balance
Cash
48,956,579
64,649,772
52,696,587
Long term investments
(31,250,307)
(28,692,112)
(35,331,977)
Excess cash
17,661,724
35,902,490
17,327,437
Stockholders' equity
(125,142,761)
(131,838,479)
(89,351,580)
Invested Capital
198,878,116
223,539,864
160,942,656
ROIC
ROCE
EV
Common stock shares outstanding
7,929
7,911
7,855
Price
54,900.00
-39.40%
Market cap
431,255,750
-30.64%
EV
413,931,102
EBITDA
(13,610,486)
(9,332,143)
(10,898,991)
EV/EBITDA
Interest
2,581,581
428,245
28,375
Interest/NOPBT